Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 11, 2021-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-
-
Mar 25, 2021- Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022
-
Mar 1, 2021-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-
-
Nov 10, 2020Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021
-
Nov 2, 2020- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th
-
Sep 10, 2020- Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration